Your browser doesn't support javascript.
loading
Pediatric systemic juvenile idiopathic arthritis-related lung disease: Description of clinical cohort and review of management.
Swanson, Chandra; Khan, Erin K; Cooper, Ashley; Ibarra, Maria; Tam-Williams, Jade.
Affiliation
  • Swanson C; Department of Pulmonary and Sleep Medicine, Children's Mercy - Kansas City, Kansas City, Missouri, USA.
  • Khan EK; Department of Pulmonary and Sleep Medicine, Children's Mercy - Kansas City, Kansas City, Missouri, USA.
  • Cooper A; Department of Pulmonary and Sleep Medicine, Children's Mercy - Kansas City, Kansas City, Missouri, USA.
  • Ibarra M; Department of Pulmonary and Sleep Medicine, Children's Mercy - Kansas City, Kansas City, Missouri, USA.
  • Tam-Williams J; Department of Pulmonary and Sleep Medicine, Children's Mercy - Kansas City, Kansas City, Missouri, USA.
Pediatr Pulmonol ; 59(3): 724-733, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38155594
ABSTRACT
CONTEXT Since the early 2010s, there has been an increased awareness of interstitial lung disease in systemic juvenile idiopathic arthritis (sJIA-LD) in pediatric patients. Despite the increase in prevalence of sJIA-LD, little is known about this disease process and effective therapeutic management.

OBJECTIVES:

To identify and characterize the disease process and management of interstitial lung disease related to systemic juvenile idiopathic arthritis. STUDY

DESIGN:

In this single-center, retrospective case series of 9 patients, we analyze demographic, clinical, radiographic, and laboratory data to corroborate common clinical characteristics and describe an approach for diagnosis and monitoring of sJIA-LD. DATA EXTRACTION All data was extracted through electronic medical records and individually reviewed by two pediatric pulmonologists and two pediatric rheumatologists.

RESULTS:

Our results were similar to other described cases of sJIA-LD as patients in our cohort were more likely to be younger, have a history of macrophage activation syndrome and prior use of biologic therapies. In contrast to prior studies, they did not present with peripheral lymphadenopathy and hepatosplenomegaly.

LIMITATIONS:

The cohort size was small and data is reflective of one center's approach to management of a rare lung disease process.

CONCLUSION:

Interstitial lung disease due to sJIA is rare and management can be difficult in these complex patients.More research is necessary to understand the increased incidence and treatment of sJIA-LD in pediatric population.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Juvenile / Lung Diseases, Interstitial / Macrophage Activation Syndrome Limits: Child / Humans Language: En Journal: Pediatr Pulmonol Journal subject: PEDIATRIA Year: 2024 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Juvenile / Lung Diseases, Interstitial / Macrophage Activation Syndrome Limits: Child / Humans Language: En Journal: Pediatr Pulmonol Journal subject: PEDIATRIA Year: 2024 Document type: Article Affiliation country: Estados Unidos